The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer

NCT06092242 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: Tas-102(Suyuan) combined with bevacizumab

Sponsor

The Second Affiliated Hospital of Shandong First Medical University